Literature DB >> 2313088

Evidence for idiotypic- and antiidiotypic B-B cellular interaction with the use of cloned antiidiotypic B cell line.

S Bitoh1, S Fujimoto, H Yamamoto.   

Abstract

Immunization of BALB/c mice with MOPC104E myeloma protein induces antiidiotypic B lymphocytes that have Id-specific enhancing activity on antibody production. The B-B cell interaction was restricted to both Igh and class II MHC. However, anti-Thy-1 and C-treated splenic B cells were maintained for more than 1 y in a mixture of Con A-stimulated splenocyte culture supernatant and synthetic medium. In applying the long term culture method, we have established a cloned B cell line named B19-1d, B19-1d cells are specific to MOPC104E or J558 cross-reactive Id and they express surface mu, lambda but no Ly-1. B19-1d do not spontaneously secrete Ig but produce them upon stimulation with bacterial LPS. The effect of B19-1d cell line on idiotypic antibody production was tested. Addition of only 10 to 100 B19-1d cells into dextran-immune B cell culture greatly enhanced the Id+ antidextran antibody responses. On the contrary, the antidextran antibody production was suppressed by the higher doses of B19-1d cells. The effective cooperation between dextran-immune B cells and B19-1d cloned B cells was restricted to class II MHC. The role of idiotypic- and antiidiotypic B-B cell interaction in immune regulation and repertoire generation was suggested.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2313088

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Regulation of levels of serum antibodies to ryegrass pollen allergen Lol pIV by an internal image anti-idiotypic monoclonal antibody.

Authors:  E M Zhou; F T Kisil
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

2.  Differences in anti-Fab antibodies in adult and late onset rheumatoid arthritis.

Authors:  F Gamerith; G J Zlabinger; O Scherak; G Kolarz; M Schemper; H Heinzl; J E Menzel
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.